SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO). With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded p
SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program, for eligible R&D activities conducted in calendar year 2025. The CIR is a French Government inc
Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.
Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.
Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.
Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year. This follows approval from AusIndustry of Immu
Detailed price information for Immutep Ltd ADR (IMMP-Q) from The Globe and Mail including charting and trades.
Detailed price information for Immutep Ltd Ord (PRRUF) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.